Last reviewed · How we verify
Clopidogrel and aspirin dual-antiplatelet therapy — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Clopidogrel and aspirin dual-antiplatelet therapy (Clopidogrel and aspirin dual-antiplatelet therapy) — Harbin Medical University.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Clopidogrel and aspirin dual-antiplatelet therapy TARGET | Clopidogrel and aspirin dual-antiplatelet therapy | Harbin Medical University | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Clopidogrel and aspirin dual-antiplatelet therapy CI watch — RSS
- Clopidogrel and aspirin dual-antiplatelet therapy CI watch — Atom
- Clopidogrel and aspirin dual-antiplatelet therapy CI watch — JSON
- Clopidogrel and aspirin dual-antiplatelet therapy alone — RSS
Cite this brief
Drug Landscape (2026). Clopidogrel and aspirin dual-antiplatelet therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/clopidogrel-and-aspirin-dual-antiplatelet-therapy. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab